Following this observation, we derived a phosphoproteomics signature that classified KMT2Ar-AML patients into two biochemically distinct groups, which we termed MLL group A (MLLGA) and MLL group B (MLLGB) (Fig. 2c, d). Here, KMT2A is linked to acute myeloid leukemia.